Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05915013 · ClinicalTrials.gov registry record · Phase 1

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

A Phase 1 study of Post Traumatic Stress Disorder and Depressive Disorder, Major, sponsored by Yale University.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT05915013 is a Phase 1 study of Post Traumatic Stress Disorder and Depressive Disorder, Major that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants, below the 1,116-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05915013, a Phase 1 study of Post Traumatic Stress Disorder and Depressive Disorder, Major, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

Conditions Studied

Post Traumatic Stress Disorder Depressive Disorder, Major

Interventions

  • DRUG Placebo
  • DRUG Ketamine
  • DRUG Perampanel

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-09-07
Est. Completion 2032-12
Phase Phase 1

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05915013

The ClinicalTrials.gov registry entry for NCT05915013 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,116-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (96% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05915013 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05915013 about?

NCT05915013 is a clinical study titled "Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response". The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid recepto...

What is the current status of trial NCT05915013?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-09-07. Estimated completion is 2032-12.

What conditions does trial NCT05915013 study?

This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Depressive Disorder, Major.

What interventions are being tested in trial NCT05915013?

The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Perampanel (DRUG).

Who is sponsoring clinical trial NCT05915013?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05915013 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Post Traumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Post Traumatic Stress Disorder

All registered trials for this condition

Depressive Disorder, Major

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.